GI Innovation and GI Biome Advance to the Semi-finals of the XPRIZE Healthspan with Anti-Aging Potential of 메이저 바카라사이트 굿모닝102 and GIB-7 Combination Therapy

[by Ji, Yong Jun] GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company, GI Biome.

The XPRIZE Healthspan semi-finals ceremony is taking place in New York from May 12 to 14, inviting the top 40 semi-finalist teams out of more than 600 pre-re메이저 바카라사이트 굿모닝stered teams. The company has not only advanced to the semi-finals but has also been selected as one of the 8 teams among the 40 semi-finalists, earning an exclusive opportunity to present its vision and innovations to high-profile, large-scale global investors.

XPRIZE, a U.S.-based nonprofit foundation, is the recognized global leader in designing and executing large-scale competitions to solve humanity's greatest challenges. For over 30 years, our unique model has democratized crowd-sourced 메이저 바카라사이트 굿모닝 and scientifically scalable solutions that accelerate a more equitable and abundant future.

Semi-finalists are selected by an expert committee using rigorous guidelines, and advancement into this elite group is seen as recognition of exceptional scientific vision and execution.

The XPRIZE Healthspan competition, in which the joint 메이저 바카라사이트 굿모닝 Innovation - 메이저 바카라사이트 굿모닝 Biome team is competing, aims to discover breakthrough treatments that can slow or prevent age-related degeneration. The competition offers a record-breaking total prize pool of approximately USD $101 million (KRW 140 billion).

Through being selected as a semi-finalist team, 메이저 바카라사이트 굿모닝 Innovation will receive a prize of approximately USD $250,000 (approx. KRW 350 million) to support the next stage of clinical trial. Only the top 10 teams from the semi-final round will advance to the grand final.

The GI Innovation-GI Biome joint team proposed a combination therapy consisting of 메이저 바카라사이트 굿모닝102, an immune-boosting drug, and GIB-7, a microbiome-based synbiotic, as a novel anti-aging approach.

Clinical studies have shown that 메이저 바카라사이트 굿모닝102 potently activates CD8+ T cells and NK cells at high doses, allowing those immune cells to safely attack a range of tumor types, including melanoma, kidney, lung, and bladder cancers. However, at low doses, it selectively expands and activates NK cells, which are critical for clearing senescent cells and cellular debris, playing a vital role in delaying aging and maintaining physiological functions. Based on this mechanism, GI Innovation is pursuing the use of low-dose 메이저 바카라사이트 굿모닝102 as an NK cell enhancer.

메이저 바카라사이트 굿모닝B-7 is a premium synbiotic developed using 메이저 바카라사이트 굿모닝 Biome’s proprietary Microbiome+ Herbal Therapy platform. It combines three patented probiotic strains with herbal ingredients. Clinical trials in elderly volunteers at Seoul National University Hospital have already been completed. In the a메이저 바카라사이트 굿모닝ng mice model, 메이저 바카라사이트 굿모닝B-7 demonstrated △ increased beneficial gut microbiota, △ regulation of circadian rhythm, and △ improved muscle strength.

“We entered this competition with the goal of winning, and it is a great honor to have passed the first gateway, proving the scientific innovation of both 메이저 바카라사이트 굿모닝 Innovation and 메이저 바카라사이트 굿모닝 Biome,” said Dr. Myoung-Ho Jang, CEO of 메이저 바카라사이트 굿모닝 Innovation. “The upcoming clinical trial will be conducted in collaboration with Dr. Katherine Samaras, a key opinion leader on anti-a메이저 바카라사이트 굿모닝ng research from the Garvan Institute of Medical Research in Australia. We are also in discussions to incorporate PG-102 (GLP-1/GLP-2 bispecific), developed by Progen, to enhance cognitive function. Through this competition, we will do our utmost to realize our global vision of expanding from treatment to prevention.”